CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 375 filers reported holding CRISPR THERAPEUTICS AG in Q1 2023. The put-call ratio across all filers is 1.09 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $59,007 | -19.1% | 1,300 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $72,982 | +24.1% | 1,300 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $58,799 | +11.3% | 1,300 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $52,845 | -37.8% | 1,300 | 0.0% | 0.00% | -50.0% |
| Q3 2022 | $85,000 | +7.6% | 1,300 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $79,000 | -10.2% | 1,300 | -7.1% | 0.00% | 0.0% |
| Q1 2022 | $88,000 | -82.4% | 1,400 | -78.8% | 0.00% | -75.0% |
| Q4 2021 | $500,000 | +179.3% | 6,600 | +312.5% | 0.01% | +166.7% |
| Q3 2021 | $179,000 | – | 1,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $27,989,046 | 33.20% |
| Gilfoyle Management LLC | 100 | $4,842 | 15.90% |
| NEA Management Company, LLC | 1,587,854 | $89,142,124 | 6.80% |
| ARK Investment Management | 7,338,447 | $411,980,394 | 2.73% |
| Nikko Asset Management Americas, Inc. | 3,533,357 | $198,327,328 | 2.09% |
| Del-Sette Capital Management, LLC | 33,661 | $1,889,729 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Merlin Capital, Inc | 8,802 | $494,144 | 1.67% |
| Green Alpha Advisors, LLC | 34,373 | $1,929,700 | 1.27% |